BioSpace News Archive

Ziopharm Oncology, Inc., a clinical-stage cellular therapy company focused on hematologic and solid tumor cancers, announced that Company management will participate in two upcoming investor conferences

Results of a longitudinal observational study to be published in JMIR Diabetes demonstrates how One Medical (Nasdaq: ONEM) incorporates an embedded diabetes management program within its membered-centered and technology-powered primary care model to deliver better health outcomes for patients, including meaningful reductions in HbA1c (blood glucose) levels.

Biostage, Inc. (OTCQB: BSTG) (“Biostage” or the “Company”), a bioengineering company developing next-generation esophageal implants based its novel Cellframe™ and Cellspan™ technology, today announced its financial results for the three months ended March 31, 2021 .

Trice Medical announced today the appointment of Ryan Hartman as Chief Commercial Officer.

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, presented new findings at the Digestive Disease Week® (DDW) 2021 virtual meeting from a survey highlighting disease burden and care-seeking behavior among adult patients with irritable bowel syndrome with constipation (IBS-C) during the COVID-19 pandemic.

Blackstone Life Sciences, the life sciences business of Blackstone (NYSE:BX), today announced the appointments of Dr. Olivier Brandicourt, former CEO of Sanofi, Dr. Omar Ishrak, former Chairman and CEO of Medtronic, Dr. Francois Nader, former CEO of NPS Pharma, and Kim Popovits, former CEO of Genomic Health, as Senior Advisors.

Spruce Biosciences Presents Phase 2 Data for Tildacerfont in Adults with Congenital Adrenal Hyperplasia at 23 rd European Congress of Endocrinology Richard Auchus, MD, PhD, Presents Phase 2 Data of Tildacerfont in Adult Classic CAH Tildacerfont Demonstrates Normalization of Elevated Hormone Levels Without Increases to Daily Steroid Doses

Bausch Health Companies Inc. announced that it has launched an offering of $1.6 billion aggregate principal amount of new senior secured notes due 2028.

BI 425809, A Novel Glycine transporter-1 (GlyT1) Inhibitor To Be Studied in First-of-its-Kind Phase III Trials, Incorporating Speech Analytics and Virtual Reality Functional Capacity Assessments

Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health,” the “Company” or the “Offeror”) announced today that it has commenced a cash tender offer (the “Tender Offer”) to purchase any and all of its outstanding 7.00% Senior Secured Notes due 2024 (the “Notes”).